Orum Therapeutics Names Chad May As Chief Scientific Officer
By Amit Chowdhry ● Jan 4, 2026
Orum Therapeutics, a biotechnology company developing degrader-antibody conjugates (DACs), has appointed Chad May, Ph.D., as Chief Scientific Officer, bringing more than two decades of oncology and immunology R&D experience spanning antibody-drug conjugates (ADCs), T-cell engagers, and next-generation therapeutic platform development.